Retatrutide vs. orforglipron: Lilly's two-horse race

Retatrutide is an injectable peptide engineered to activate the GLP-1, GIP, and glucagon receptors simultaneously. The GLP-1 and GIP components suppress appetite and improve insulin response; glucagon-receptor activation appears to increase resting energy expenditure, which is the leading hypothesis for retatrutide's unusually large weight-loss effect. [1]

Orforglipron targets only the GLP-1 receptor — but it does so as a small molecule, not a peptide. That single difference matters enormously: small molecules survive stomach acid and gut enzymes, so orforglipron can be swallowed as an ordinary tablet once daily, without the absorption-enhancing formulation that oral semaglutide requires and without strict fasting or water restrictions. [2]

In the Phase 2 obesity trial, participants on the highest 12 mg dose of retatrutide lost an average of 24.2% of body weight at 48 weeks, vs. about 2% on placebo. [1]

In orforglipron's Phase 2 obesity trial, participants on the highest studied dose lost an average of roughly 14.7% of body weight at 36 weeks, vs. about 2.3% on placebo. [2] In the larger Phase 3 ATTAIN-1 trial, topline results reported approximately 12.4% average weight loss at 72 weeks at the highest dose. [4]

The usual caveats apply: different trials, durations, titration schedules, and populations. The Phase-2-to-3 attenuation visible in orforglipron's numbers (roughly 14.7% to 12.4%) is also a useful reminder that retatrutide's 24% Phase 2 figure may moderate somewhat in Phase 3. Even so, the two drugs clearly occupy different efficacy tiers — that is by design, not by accident.

In both programs, the most common adverse events were nausea, vomiting, diarrhea, and constipation — mostly mild-to-moderate and concentrated during dose escalation. [2] Discontinuation due to adverse events was higher on active drug than on placebo in both programs, as is typical for the class.

Retatrutide's distinguishing signal is a modest, dose-dependent increase in resting heart rate, presumed to relate to its glucagon-receptor activity. [1] Orforglipron, as a GLP-1-only agonist, has not shown a comparable signal in published data, though its long-term cardiovascular profile is being established in ongoing outcomes work.

Retatrutide is given as a once-weekly subcutaneous injection, titrated in four-week steps; Phase 2 studied maintenance doses up to 12 mg. As a peptide, it requires refrigeration and an injection device.

Orforglipron is a once-daily oral tablet. Phase 2 studied doses up to 45 mg daily; Phase 3 maintenance doses top out at 36 mg daily. Crucially, it can be taken without the fasting and water-volume restrictions that make oral semaglutide awkward for many patients. [5]

Peptide drugs like retatrutide require complex synthesis, sterile fill-finish, injection pens, and an unbroken cold chain from factory to patient. Every one of those constraints showed up as a real-world shortage during the semaglutide and tirzepatide launches.

Orforglipron, as a small molecule, can be manufactured by conventional chemical synthesis at a fraction of the cost, stored at room temperature, and shipped as ordinary tablets. That opens markets where cold chains are unreliable, removes the injection-device bottleneck entirely, and gives Lilly enormous pricing flexibility. For global access — and for the tens of millions of patients who decline injections on principle — this is arguably the more important of Lilly's two drugs, even though it is the less potent one.

Read together, Lilly's pipeline covers the two axes that will define the obesity-drug market: efficacy and accessibility. Retatrutide is the flagship for patients who need the largest possible weight loss — competing head-on with Novo Nordisk's CagriSema at the top of the data table. Orforglipron is the vehicle for earlier-line treatment, maintenance therapy after injectable-induced weight loss, and price-sensitive health systems.

It is plausible the two drugs end up used sequentially in the same patient: retatrutide to achieve a large initial reduction, orforglipron as a convenient long-term maintenance agent. That sequencing question will be studied formally only after both are approved.

These are not really competitors — they are complements inside the same company. The honest framing is a trade-off: roughly 24% weight loss with a weekly injection versus roughly 12–15% with a daily pill, both pending Phase 3 confirmation and FDA review.

Both drugs are investigational. Any product sold online as retatrutide or orforglipron is unregulated and unverified. When either approves, treatment decisions belong with a licensed clinician. This page is informational and is not medical advice.